CoChat

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

Open access
Xiang, Xianyuan, Werner, Georg, Bohrmann, Bernd, Liesz, Arthur, Mazaheri, Fargol, Capell, Anja, Feederle, Regina, Knuesel, Irene, Kleinberger, Gernot, Haass, Christian · 2016 · EMBO Molecular Medicine

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Immunotherapeutic approaches are currently the most advanced treatments for Alzheimer's disease (AD). Antibodies against amyloid β‐peptide (Aβ) bind to amyloid plaques and induce their clearance by microglia via Fc receptor‐mediated phagocytosis. Dysfunctions of microglia may play a pivotal role in AD pathogenesis and could result in reduced efficacy of antibody‐mediated Aβ clearance. Recently, heterozygous mutations in the triggering receptor expressed on myeloid cells 2 (TREM2), a microglial gene involved in phagocytosis, were genetically linked to late onset AD. Loss of TREM2 reduces the ability of microglia to engulf Aβ. We have now investigated whether loss of TREM2 affects the efficacy of immunotherapeutic approaches. We show that anti‐Aβ antibodies stimulate Aβ uptake and amyloid plaque clearance in a dose‐dependent manner in the presence or absence of TREM2. However, TREM2‐deficient N9 microglial cell lines, macrophages as well as primary microglia showed significantly reduced uptake of antibody‐bound Aβ and as a consequence reduced clearance of amyloid plaques. Titration experiments revealed that reduced efficacy of amyloid plaque clearance by Trem2 knockout cells can be compensated by elevating the concentration of therapeutic antibodies. TREM2‐deficient phagocytic cells do not uptake antibody‐bound Aβ well, resulting in reduced clearance of amyloid plaques. This, however, can be compensated by elevated concentrations of immunotherapeutic antibodies, highlighting that monitoring microglia function in Alzheimer's disease is important. TREM2‐deficient phagocytic cells do not uptake antibody‐bound Aβ well, resulting in reduced clearance of amyloid plaques. This, however, can be compensated by elevated concentrations of immunotherapeutic antibodies, highlighting that monitoring microglia function in Alzheimer's disease is important.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201606370

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 TREM2 deficiency reduces efficacy of antibody‐stimulated Aβ uptake by phagocytic cells Schematic of the mouse Trem2 locus and the TREM2 protein. Sequence alignment of wild‐type N9 (N9 wt) and TREM2 mutant N9 (N9 mu) surrounding the gRNA target site. The gRNA sequence is in cyan, and protospacer‐adjacent motif (PAM) is marked with a line. The single nucleotide insertion is labeled in red. Schematic representation of wild‐type TREM2 (NP_112544.1) and CRISPR/Cas9‐modified TREM2 (N9 mu). TM, transmembrane domain; SP, signal peptide.Western blot analysis of lysates and media from wt and mutant N9 cells (N9 wt /mu) using the antibody anti‐murine TREM2 (clone 5F4), which is raised against the murine TREM2 extracellular domain. sTREM2, soluble TREM2. *indicate unspecific bands. Calnexin was used as a loading control.Phagocytosis of 1 μM HiLyte™ Fluor 488 Aβ1‐42 (fAβ42) by N9 wt and N9 mu in the presence or absence of antibody 2D8 or the non‐binding antibody 6687. Cytochalasin D (CytoD, 10 mM) was used as control to verify phagocytic uptake. (n = 4, ± SEM; two‐way ANOVA, interaction P = 0.61, genotype P < 0.0001, treatment P = 0.0001; post hoc tests wt vs. mu for the following conditions: fAβ42 P = 0.0043, fAβ42‐2D8 P = 0.0436).Western blot of BMDM derived from wt and Trem2 knockout (ko) animals using antibody 5F4. *indicate unspecific bands.Phagocytosis of fAβ42 by BMDM from wt and Trem2 ko animals in the presence or absence of 2D8, or the non‐binding control antibody 6687. (n = 3, ± SEM; two‐way ANOVA, interaction P = 0.0005, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42 P = 0.0021, fAβ42‐2D8 1 μg/ml P < 0.0001, fAβ42‐2D8 5 μg/ml P < 0.0001, fAβ42‐2D8 10 μg/ml P < 0.0001, fAβ42/6687 10 μg/ml P = 0.0007).Quantification of relative fAβ42 uptake to lowest antibody concentration used (n = 3, ± SEM).Phagocytosis of fAβ42 by BMDM from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). (n = 4, ± SEM; two‐way ANOVA, interaction P = 0.0223, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42‐mAb11 1 μg/ml P = 0.0391, fAβ42‐mAb11 5 μg/ml P = 0.0069, fAβ42‐mAb11 10 μg/ml P < 0.0001, fAβ42‐mAb11 20 μg/ml P = 0.0001, fAβ42‐mAb11 50 μg/ml P < 0.0001).Quantification of relative fAβ42 uptake to lowest antibody concentration used (n = 4, ± SEM).Recombinant mouse sTREM2 does not rescue fAβ42 uptake in Trem2‐deficient BMDM. Increasing amounts of sTREM2 were added to the media of wt or Trem2 ko BMDM in the presence or absence of mAb11 (10 μg/ml) (n = 4, ± SEM).Western blot of primary microglia from wt or Trem2 ko animals using antibody 5F4. *indicate unspecific bands.Phagocytosis of fAβ42 by primary microglia from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). (n = 5, ± SEM; two‐way ANOVA, interaction P = 0.4797, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42‐mAb11 5 μg/ml P = 0.0449, fAβ42‐mAb11 10 μg/ml P = 0.0370, fAβ42‐mAb11 20 μg/ml P = 0.0299, fAβ42‐mAb11 50 μg/ml P = 0.0120).Quantification of relative fAβ42 uptake to lowest antibody concentration used (n = 5, ± SEM).Data information: (C, E, G, K) Quantification of internalized fAβ42 was normalized to wt without antibody. Bonferroni‐corrected pair‐wise post hoc tests were used.Source data are available online for this figure.
Figure 1 TREM2 deficiency reduces efficacy of antibody‐stimulated Aβ uptake by phagocytic cells Schematic of the mouse Trem2 locus and the TREM2 protein. Sequence alignment of wild‐type N9 (N9 wt) and TREM2 mutant N9 (N9 mu) surrounding the gRNA target site. The gRNA sequence is in cyan, and protospacer‐adjacent motif (PAM) is marked with a line. The single nucleotide insertion is labeled in red. Schematic representation of wild‐type TREM2 (NP_112544.1) and CRISPR/Cas9‐modified TREM2 (N9 mu). TM, transmembrane domain; SP, signal peptide.Western blot analysis of lysates and media from wt and mutant N9 cells (N9 wt /mu) using the antibody anti‐murine TREM2 (clone 5F4), which is raised against the murine TREM2 extracellular domain. sTREM2, soluble TREM2. *indicate unspecific bands. Calnexin was used as a loading control.Phagocytosis of 1 μM HiLyte™ Fluor 488 Aβ1‐42 (fAβ42) by N9 wt and N9 mu in the presence or absence of antibody 2D8 or the non‐binding antibody 6687. Cytochalasin D (CytoD, 10 mM) was used as control to verify phagocytic uptake. (n = 4, ± SEM; two‐way ANOVA, interaction P = 0.61, genotype P < 0.0001, treatment P = 0.0001; post hoc tests wt vs. mu for the following conditions: fAβ42 P = 0.0043, fAβ42‐2D8 P = 0.0436).Western blot of BMDM derived from wt and Trem2 knockout (ko) animals using antibody 5F4. *indicate unspecific bands.Phagocytosis of fAβ42 by BMDM from wt and Trem2 ko animals in the presence or absence of 2D8, or the non‐binding control antibody 6687. (n = 3, ± SEM; two‐way ANOVA, interaction P = 0.0005, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42 P = 0.0021, fAβ42‐2D8 1 μg/ml P < 0.0001, fAβ42‐2D8 5 μg/ml P < 0.0001, fAβ42‐2D8 10 μg/ml P < 0.0001, fAβ42/6687 10 μg/ml P = 0.0007).Quantification of relative fAβ42 uptake to lowest antibody concentration used (n = 3, ± SEM).Phagocytosis of fAβ42 by BMDM from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). (n = 4, ± SEM; two‐way ANOVA, interaction P = 0.0223, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42‐mAb11 1 μg/ml P = 0.0391, fAβ42‐mAb11 5 μg/ml P = 0.0069, fAβ42‐mAb11 10 μg/ml P < 0.0001, fAβ42‐mAb11 20 μg/ml P = 0.0001, fAβ42‐mAb11 50 μg/ml P < 0.0001).Quantification of relative fAβ42 uptake to lowest antibody concentration used (n = 4, ± SEM).Recombinant mouse sTREM2 does not rescue fAβ42 uptake in Trem2‐deficient BMDM. Increasing amounts of sTREM2 were added to the media of wt or Trem2 ko BMDM in the presence or absence of mAb11 (10 μg/ml) (n = 4, ± SEM).Western blot of primary microglia from wt or Trem2 ko animals using antibody 5F4. *indicate unspecific bands.Phagocytosis of fAβ42 by primary microglia from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). (n = 5, ± SEM; two‐way ANOVA, interaction P = 0.4797, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42‐mAb11 5 μg/ml P = 0.0449, fAβ42‐mAb11 10 μg/ml P = 0.0370, fAβ42‐mAb11 20 μg/ml P = 0.0299, fAβ42‐mAb11 50 μg/ml P = 0.0120).Quantification of relative fAβ42 uptake to lowest antibody concentration used (n = 5, ± SEM).Data information: (C, E, G, K) Quantification of internalized fAβ42 was normalized to wt without antibody. Bonferroni‐corrected pair‐wise post hoc tests were used.Source data are available online for this figure.CC BY · PubMed Central
Figure 2 Increased Fcγ‐receptors expression and enhanced Syk phosphorylation in TREM2‐deficient BMDM Representative histograms for Fcγ‐receptors‐PE (FcγR‐PE) expression levels as used for quantification. Stacked histograms for log PE fluorescence intensity of wt and Trem2 ko BMDM are shown for the respective FcγR (I, IIB/III, and IV).Relative quantification of cell surface levels of FcγR molecules. Absolute number of cell surface FcγR‐PE molecules was determined by the BD QuantiBRITE® method (see methods section for details) and normalized to expression levels of the respective wt control. (n = 4, ± SEM, t‐test, two‐tailed; wt vs. ko: FcγRI‐PE P = 0.0008, FcγRIIB/III‐PE P = 0.0033, FcγRIV‐PE P = 0.7001).mRNA levels of FcγR are increased in Trem2 ko BMDM. Fold changes of the respective FcγR (I, IIB, III, IV) mRNA levels in Trem2 ko BMDM were determined by quantitative real‐time PCR. (n = 6, ± SEM; one‐sample t‐test, two‐tailed; wt vs. ko: FcγRI P = 0.0118, FcγRIIB P = 0.0006, FcγRIII P = 0.0004, FcγRIV P = 0.0284)Phosphorylated Syk (P‐Syk) and total Syk (T‐Syk) levels were determined by Western blotting in lysates from wt and Trem2 ko BMDM after 1 h treatment with Aβ alone, together with antibody 2D8 (Aβ‐2D8), or an isotype control (Aβ‐IC). Actin was used as a loading control.Quantification of P‐Syk normalized to T‐Syk. (n = 4, ± SEM; 2 way ANOVA, interaction P = 0.0490, genotype P = 0.0898, treatment P < 0.0001. Bonferroni‐corrected pair‐wise post hoc tests, **P = 0.0075 vs. wt). Source data are available online for this figure.
Figure 2 Increased Fcγ‐receptors expression and enhanced Syk phosphorylation in TREM2‐deficient BMDM Representative histograms for Fcγ‐receptors‐PE (FcγR‐PE) expression levels as used for quantification. Stacked histograms for log PE fluorescence intensity of wt and Trem2 ko BMDM are shown for the respective FcγR (I, IIB/III, and IV).Relative quantification of cell surface levels of FcγR molecules. Absolute number of cell surface FcγR‐PE molecules was determined by the BD QuantiBRITE® method (see methods section for details) and normalized to expression levels of the respective wt control. (n = 4, ± SEM, t‐test, two‐tailed; wt vs. ko: FcγRI‐PE P = 0.0008, FcγRIIB/III‐PE P = 0.0033, FcγRIV‐PE P = 0.7001).mRNA levels of FcγR are increased in Trem2 ko BMDM. Fold changes of the respective FcγR (I, IIB, III, IV) mRNA levels in Trem2 ko BMDM were determined by quantitative real‐time PCR. (n = 6, ± SEM; one‐sample t‐test, two‐tailed; wt vs. ko: FcγRI P = 0.0118, FcγRIIB P = 0.0006, FcγRIII P = 0.0004, FcγRIV P = 0.0284)Phosphorylated Syk (P‐Syk) and total Syk (T‐Syk) levels were determined by Western blotting in lysates from wt and Trem2 ko BMDM after 1 h treatment with Aβ alone, together with antibody 2D8 (Aβ‐2D8), or an isotype control (Aβ‐IC). Actin was used as a loading control.Quantification of P‐Syk normalized to T‐Syk. (n = 4, ± SEM; 2 way ANOVA, interaction P = 0.0490, genotype P = 0.0898, treatment P < 0.0001. Bonferroni‐corrected pair‐wise post hoc tests, **P = 0.0075 vs. wt). Source data are available online for this figure.CC BY · PubMed Central
Figure 3 Engulfment of fibrillar Aβ by BMDM and primary microglia AA schematic shows 10‐μm cryosections of unfixed brain from 6‐month‐old APP/PS1 mice, which show a high amyloid plaque burden (right panel with methoxy‐X04 staining), were incubated with antibody for 1 h, followed by adding BMDM or primary microglia on top of the sections. After 24 h incubation, sections were analyzed by immunostaining or immunoblotting.BmAb11 but not the isotype control (IC) co‐localized with methoxy‐X04. Scale bar: 10 μm.C, DBMDM (C) or primary microglia (D) were cultured on cryosections pre‐incubated with mAb11 (1 μg/ml). After 24 h, sections were processed for immunostaining using antibody against CD68 to identify myeloid cells and methoxy‐X04 staining to visualize Aβ. Note that both cell types internalize Aβ into intracellular vesicles (right panels show enlargement of insets). Scale bar: 10 μm.
Figure 3 Engulfment of fibrillar Aβ by BMDM and primary microglia AA schematic shows 10‐μm cryosections of unfixed brain from 6‐month‐old APP/PS1 mice, which show a high amyloid plaque burden (right panel with methoxy‐X04 staining), were incubated with antibody for 1 h, followed by adding BMDM or primary microglia on top of the sections. After 24 h incubation, sections were analyzed by immunostaining or immunoblotting.BmAb11 but not the isotype control (IC) co‐localized with methoxy‐X04. Scale bar: 10 μm.C, DBMDM (C) or primary microglia (D) were cultured on cryosections pre‐incubated with mAb11 (1 μg/ml). After 24 h, sections were processed for immunostaining using antibody against CD68 to identify myeloid cells and methoxy‐X04 staining to visualize Aβ. Note that both cell types internalize Aβ into intracellular vesicles (right panels show enlargement of insets). Scale bar: 10 μm.CC BY · PubMed Central
Figure 4 TREM2 deficiency reduces antibody‐mediated amyloid plaque clearance ABMDM from wt or Trem2 ko mice were cultured on APP/PS1 mice brain cryosections incubated with or without mAb11 (1 μg/ml) or an isotype control (IC; 1 μg/ml) for 24 h. Sections were then probed with methoxy‐X04. Scale bar, 500 μm.BThe amyloid plaque load was quantified from the entire sagittal section. Sections incubated with medium (no cell) were set as baseline. (n = 6, ± SEM; two‐way ANOVA, interaction P < 0.0001, genotype P < 0.0001, treatment P < 0.0001; Tukey's multiple comparisons tests; wt vs. ko for the following conditions: no antibody P = 0.0304, IC P = 0.0049, mAb11 P = 0.0212; wt: IC vs. wt: mAb11 P = 0.0008; ko: IC vs. ko: mAb11 P = 0.0001).C, DEqual numbers of wt and Trem2 ko BMDM were added, and cell numbers were analyzed after termination of experiments by quantifying the CD68‐positive cells on top of the sections. (n = 4, ± SEM; t‐test; n.s., non‐significant, P = 0.5004). Scale bar, 200 μm.EAβ was extracted by urea buffer from replicate slices of the experiment shown in (A), and total Aβ was identified by Western blotting. Source data are available online for this figure.
Figure 4 TREM2 deficiency reduces antibody‐mediated amyloid plaque clearance ABMDM from wt or Trem2 ko mice were cultured on APP/PS1 mice brain cryosections incubated with or without mAb11 (1 μg/ml) or an isotype control (IC; 1 μg/ml) for 24 h. Sections were then probed with methoxy‐X04. Scale bar, 500 μm.BThe amyloid plaque load was quantified from the entire sagittal section. Sections incubated with medium (no cell) were set as baseline. (n = 6, ± SEM; two‐way ANOVA, interaction P < 0.0001, genotype P < 0.0001, treatment P < 0.0001; Tukey's multiple comparisons tests; wt vs. ko for the following conditions: no antibody P = 0.0304, IC P = 0.0049, mAb11 P = 0.0212; wt: IC vs. wt: mAb11 P = 0.0008; ko: IC vs. ko: mAb11 P = 0.0001).C, DEqual numbers of wt and Trem2 ko BMDM were added, and cell numbers were analyzed after termination of experiments by quantifying the CD68‐positive cells on top of the sections. (n = 4, ± SEM; t‐test; n.s., non‐significant, P = 0.5004). Scale bar, 200 μm.EAβ was extracted by urea buffer from replicate slices of the experiment shown in (A), and total Aβ was identified by Western blotting. Source data are available online for this figure.CC BY · PubMed Central
Figure 5 Compensation of reduced amyloid plaque clearance by elevated antibody dose Cryosections from unfixed brain of 6‐month‐old APP/PS1 mice were pre‐incubated with increasing concentrations of mAb11 (0.001, 0.01, 0.1, 1, 5 μg/ml). BMDM from wt or Trem2 ko mice were added for 24 h. Sections were stained with methoxy‐X04. Scale bar, 500 μm.Methoxy‐X04 signals were quantified from the entire sagittal section. (n = 5, ± SEM; two‐way ANOVA, interaction P = 0.0082, genotype P < 0.0001, treatment P < 0.0001. Fisher's LSD post hoc comparisons; * show statistics between wt and ko under the same experimental condition. # in black shows wt compares to no‐antibody stimulation; # in gray shows ko compares to no‐antibody stimulation; wt vs. ko for the following conditions: no antibody P = 0.0053, mAb11 0.001 μg/ml P = 0.0003, mAb11 0.01 μg/ml P < 0.0001, mAb11 0.1 μg/ml P = 0.0001, mAb11 1 μg/ml P = 0.0007, mAb11 5 μg/ml P = 0.0011; following conditions compare to wt/no antibody: wt/mAb11 0.01 μg/ml P = 0.0166, wt/mAb11 0.1 μg/ml P = 0.0002, wt/mAb11 1 μg/ml P < 0.0001, wt/mAb11 5 μg/ml P < 0.0001; following conditions compare to ko/no antibody: ko/mAb11 0.1 μg/ml P = 0.0099, ko/mAb11 1 μg/ml P < 0.0001, ko/mAb11 5 μg/ml P < 0.0001.
Figure 5 Compensation of reduced amyloid plaque clearance by elevated antibody dose Cryosections from unfixed brain of 6‐month‐old APP/PS1 mice were pre‐incubated with increasing concentrations of mAb11 (0.001, 0.01, 0.1, 1, 5 μg/ml). BMDM from wt or Trem2 ko mice were added for 24 h. Sections were stained with methoxy‐X04. Scale bar, 500 μm.Methoxy‐X04 signals were quantified from the entire sagittal section. (n = 5, ± SEM; two‐way ANOVA, interaction P = 0.0082, genotype P < 0.0001, treatment P < 0.0001. Fisher's LSD post hoc comparisons; * show statistics between wt and ko under the same experimental condition. # in black shows wt compares to no‐antibody stimulation; # in gray shows ko compares to no‐antibody stimulation; wt vs. ko for the following conditions: no antibody P = 0.0053, mAb11 0.001 μg/ml P = 0.0003, mAb11 0.01 μg/ml P < 0.0001, mAb11 0.1 μg/ml P = 0.0001, mAb11 1 μg/ml P = 0.0007, mAb11 5 μg/ml P = 0.0011; following conditions compare to wt/no antibody: wt/mAb11 0.01 μg/ml P = 0.0166, wt/mAb11 0.1 μg/ml P = 0.0002, wt/mAb11 1 μg/ml P < 0.0001, wt/mAb11 5 μg/ml P < 0.0001; following conditions compare to ko/no antibody: ko/mAb11 0.1 μg/ml P = 0.0099, ko/mAb11 1 μg/ml P < 0.0001, ko/mAb11 5 μg/ml P < 0.0001.CC BY · PubMed Central
Figure EV1 BMDM and primary microglia are positive for CD11b Surface staining of CD11b was analyzed using flow cytometry. About 97.1% bone marrow‐derived macrophages (BMDM) were positive for CD11b.Primary microglia from mixed glial culture were 90.4% positive for CD11b.
Figure EV1 BMDM and primary microglia are positive for CD11b Surface staining of CD11b was analyzed using flow cytometry. About 97.1% bone marrow‐derived macrophages (BMDM) were positive for CD11b.Primary microglia from mixed glial culture were 90.4% positive for CD11b.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 183

Metadata

Authors
Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • F. Hoffmann-La Roche AG (CH)
  • Munich Cluster for Systems Neurology (DE)
  • German Center for Neurodegenerative Diseases (DE)
Corresponding author
Haass, Christian
Venue
EMBO Molecular Medicine
Published
2016-07-08
Volume
8
Issue
9
Pages
992-1004
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2473453806
Cited by
183
References
53
Citations by year
2026: 12 · 2025: 14 · 2024: 11 · 2023: 15 · 2022: 15 · 2021: 18 · 2020: 30 · 2019: 20 · 2018: 21 · 2017: 23 · 2016: 4
FWCI
18.23
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
  • Site cant be reached (submittedVersion)
  • DZNE Pub (submittedVersion, other-oa)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
  • Journal of Neurochemistry
Funders
  • Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy)
  • European Research Council (ERC grant Agreement No. 321366‐Amyloid)
  • Legacy of Mrs. Ammer
  • The MetLife Award
  • Cure Alzheimer's Fund
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
TREM2, Alzheimer's disease, amyloid-beta, anti-amyloid immunotherapy, microglia, phagocytosis, amyloid plaque clearance, macrophages, Fc receptors
MeSH terms
Amyloid, Animals, Cells, Cultured, Membrane Glycoproteins, Mice, Inbred C57BL, Neuroglia, Phagocytosis, Receptors, Immunologic, Mice, Knockout

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. https://app.cochat.ai/papers/10.15252/emmm.201606370
The paper
Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C. (2016). TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201606370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.